UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 140

Sortiert nach

Racial disparities in commercial U.S. oocyte donors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18501-e18501

2022

Volltextzugriff (PDF)

The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9609-TPS9609

2023

Volltextzugriff (PDF)

Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese postmenopausal women at increased risk for endometrial cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1551-1551

2017

Volltextzugriff (PDF)

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

Journal of clinical oncology, 2023-01, Vol.41 (2), p.154-162

2023

Volltextzugriff (PDF)

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS7082-TPS7082

2023

Volltextzugriff (PDF)

A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA2023-LBA2023

2023

Volltextzugriff (PDF)

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16110-e16110

2023

Volltextzugriff (PDF)

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5627-TPS5627

2023

Volltextzugriff (PDF)

Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8014-8014

2022

Volltextzugriff (PDF)

Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20021-e20021

2023

Volltextzugriff (PDF)

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11517-11517

2021

Volltextzugriff (PDF)

Postoperative radiotherapy in Merkel cell carcinoma (MCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9575-9575

2021

Volltextzugriff (PDF)

Long-term follow up of selinexor maintenance in patients with TP53 wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study

Journal of clinical oncology, 2023-07, Vol.41 (36_suppl), p.427956-427956

2023

Volltextzugriff (PDF)

Bioinformatic analysis of selinexor-induced gene expression in patient-derived-chordomas to reveal mechanisms of action leading to tumor growth inhibition

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e23502-e23502

2020

Volltextzugriff (PDF)

Effect of local therapies on survival in patients with metastatic adrenocortical carcinoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17114-e17114

2020

Volltextzugriff (PDF)

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8006-8006

2021

Volltextzugriff (PDF)

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5610-TPS5610

2021

Volltextzugriff (PDF)

Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18595-e18595

2022

Volltextzugriff (PDF)

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

Journal of clinical oncology, 2004, Vol.22 (23), p.4665-4672

2004

Volltextzugriff (PDF)

Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12025-12025

2020

Volltextzugriff (PDF)

5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.148-148

2021

Volltextzugriff (PDF)

It starts at the top: An analysis of female representation in academic medical oncology (MO), radiation oncology (RO), and surgical oncology (SO) program leadership positions

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.10520-10520

2019

Volltextzugriff (PDF)

Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA- mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1038-1038

2019

Volltextzugriff (PDF)

A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7001-7001

2019

Volltextzugriff (PDF)

Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.336-336

2019

Volltextzugriff (PDF)

1 – 25 von 140

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(140)

Publikationsform

Artikel
(140)

Sprache

Englisch
(140)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Racial disparities in commercial U.S. oocyte donors

The DIET study: A randomized controlled trial of a high fiber diet in cancer patients (pts) receiving immune checkpoint blockade (ICB)

Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese postmenopausal women at increased risk for endometrial cancer

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma

Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1

Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS)

Postoperative radiotherapy in Merkel cell carcinoma (MCC)

Long-term follow up of selinexor maintenance in patients with TP53 wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study

Bioinformatic analysis of selinexor-induced gene expression in patient-derived-chordomas to reveal mechanisms of action leading to tumor growth inhibition

Effect of local therapies on survival in patients with metastatic adrenocortical carcinoma

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer

Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer

5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC

It starts at the top: An analysis of female representation in academic medical oncology (MO), radiation oncology (RO), and surgical oncology (SO) program leadership positions

Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA- mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial

A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML)

Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC)

Aktive Filter

Suchergebnisse filtern